A carregar...

Evaluation of Tyrosine Kinase Inhibitor Combinations for Glioblastoma Therapy

Glioblastoma multiforme (GBM) is the most common intracranial cancer but despite recent advances in therapy the overall survival remains about 20 months. Whole genome exon sequencing studies implicate mutations in the receptor tyrosine kinase pathways (RTK) for driving tumor growth in over 80% of GB...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Joshi, Avadhut D., Loilome, Watcharin, Siu, I-Mei, Tyler, Betty, Gallia, Gary L., Riggins, Gregory J.
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2012
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3462750/
https://ncbi.nlm.nih.gov/pubmed/23056179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0044372
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!